Lumayag, Rodolfo M.

HRN: 18-71-24  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/17/2026
CEFTAZIDIME 1GM (VIAL)
04/17/2026
04/24/2026
IV
2g
Q8
Cap MR
Checking Initial Appropriateness 
04/17/2026
AZITHROMYCIN 500MG TABLET (TAB)
04/17/2026
04/20/2026
ORAL
500
OD
Cap MR
Checking Initial Appropriateness 
04/17/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
04/17/2026
04/17/2026
IV
4.5g
Now As LD
CAP HR
Checking Initial Appropriateness 
04/17/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
04/17/2026
04/23/2026
IV
2.25g
Q6h
CAP-HR
Checking Initial Appropriateness 
04/17/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
04/17/2026
04/23/2026
IV
2.25g
Q6h
CAP-HR
Checking Initial Appropriateness 
04/20/2026
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
04/20/2026
04/27/2026
IV
4.5g
Q8H
Pneumonia
Checking Initial Appropriateness 
04/26/2026
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
04/26/2026
05/03/2026
IV
1000mg
Q24
Cap HR
Checking Initial Appropriateness 
05/04/2026
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/04/2026
05/05/2026
IV
1000mg
Od
Cap Hr
Checking Initial Appropriateness 
05/14/2026
RIFAXIMIN 200MG (TAB)
05/14/2026
05/21/2026
PER NGT
200mg
TID
Bleeding Doverticulitis
Checking Initial Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: